| Multilocus sequence typing as a replacement for serotyping in Salmonella enterica SB Mark Achtman, John Wain, François-Xavier Weill, Satheesh Nair, Zhemin ... PLoS Pathog 8 (6), e1002776, 2012 | 747 | 2012 |
| Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane A Sabnis, KLH Hagart, A Klöckner, M Becce, LE Evans, RCD Furniss, ... elife 10, e65836, 2021 | 212 | 2021 |
| Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections JL Vincent, D Brealey, N Libert, NE Abidi, M O’Dwyer, K Zacharowski, ... Critical care medicine 43 (11), 2283-2291, 2015 | 185 | 2015 |
| Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches H Lund-Palau, AR Turnbull, A Bush, E Bardin, L Cameron, O Soren, ... Expert review of respiratory medicine 10 (6), 685-697, 2016 | 160 | 2016 |
| Three Pathogenicity Islands of Vibrio cholerae Can Excise from the Chromosome and Form Circular Intermediates RA Murphy, EF Boyd Journal of bacteriology 190 (2), 636-647, 2008 | 148 | 2008 |
| Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis WD Smith, E Bardin, L Cameron, CL Edmondson, KV Farrant, I Martin, ... FEMS microbiology letters 364 (14), fnx121, 2017 | 126 | 2017 |
| Neutral Genomic Microevolution of a Recently Emerged Pathogen, Salmonella enterica Serovar Agona Z Zhou, A McCann, E Litrup, R Murphy, M Cormican, S Fanning, D Brown, ... PLoS genetics 9 (4), e1003471, 2013 | 102 | 2013 |
| The immunomodulatory drug glatiramer acetate is also an effective antimicrobial agent that kills Gram-negative bacteria SH Christiansen, RA Murphy, K Juul-Madsen, M Fredborg, ML Hvam, ... Scientific Reports 7 (1), 15653, 2017 | 37 | 2017 |
| Population structures in the SARA and SARB reference collections of Salmonella enterica according to MLST, MLEE and microarray hybridization M Achtman, J Hale, RA Murphy, EF Boyd, S Porwollik Infection, Genetics and Evolution 16, 314-325, 2013 | 30 | 2013 |
| Transforming microbial genotyping: a robotic pipeline for genotyping bacterial strains B O’Farrell, JK Haase, V Velayudhan, RA Murphy, M Achtman PLoS One 7 (10), e48022, 2012 | 20 | 2012 |
| Revival of Seeliger's historical ‘Special Listeria Culture Collection’ JK Haase, RA Murphy, KR Choudhury, M Achtman Environmental Microbiology 13 (12), 3163-3171, 2011 | 17 | 2011 |
| Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at? JC Davies, E Alton, A Simbo, R Murphy, I Seth, K Williams, M Somerville, ... European Respiratory Journal 54 (5), 2019 | 13 | 2019 |
| Impact of T2R38 Receptor Polymorphisms on Pseudomonas aeruginosa Infection in Cystic Fibrosis AR Turnbull, R Murphy, V Behrends, H Lund-Palau, A Simbo, M Mariveles, ... American Journal of Respiratory and Critical Care Medicine 197 (12), 1635-1638, 2018 | 9 | 2018 |
| Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates LA Robinson, ACZ Collins, RA Murphy, JC Davies, LP Allsopp Frontiers in Microbiology 13, 1042505, 2023 | 5 | 2023 |
| Pseudomonas aeruginosa in the Cystic Fibrosis Lung J King, R Murphy, JC Davies Pseudomonas aeruginosa: Biology, Pathogenesis and Control Strategies, 347-369, 2022 | 5 | 2022 |
| How Genomics Has Shaped Our Understanding of the Evolution and Emergence of Pathogenic Vibrio cholerae S Almagro‐Moreno, RA Murphy, EF Boyd Genomes of foodborne and waterborne pathogens, 85-99, 2010 | 4 | 2010 |
| Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa RA Murphy, M Coates, S Thrane, A Sabnis, J Harrison, S Schelenz, ... Microbiology Spectrum 10 (4), 2022 | 2 | 2022 |
| S75 The T2R38 bitter taste receptor as a modifier of host response to pseudomonas aeruginosa in cystic fibrosis: does T2R38 genotype impact on clinical infection? A Turnbull, H Lund-Palau, R Murphy, A Simbo, A Shoemark, K Wong, ... Thorax 71 (Suppl 3), A44-A44, 2016 | 2 | 2016 |
| SYNERGY WITH GLATIRAMER ACETATE REDUCES TOBRAMYCIN MINIMUM INHIBITORY CONCENTRATIONS AGAINST PSEUDOMONAS AERUGINOSA FROM CYSTIC FIBROSIS AIRWAYS RA Murphy, S Thrane, S Schelenz, J Harrison, T Vorup-Jensen, ... PEDIATRIC PULMONOLOGY 55, S154-S155, 2020 | 1 | 2020 |
| M5 The multiple sclerosis drug, glatiramer acetate, acts as a resistance breaker with antibiotics from different classes against cystic fibrosis strains of pseudomonas aeruginosa RA Murphy, J Harrison, S Schelenz, JC Davies Thorax 74 (Suppl 2), A236-A237, 2019 | 1 | 2019 |
Jane DaviesProfessor of Paediatric Respirology & Experimental MedicineVerified email at imperial.ac.uk
